163 related articles for article (PubMed ID: 35444058)
21. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
McKay RR; Leucht K; Xie W; Jegede O; Braun DA; Atkins MB; Grimm MO; Choueiri TK
Oncologist; 2024 Apr; 29(4):324-331. PubMed ID: 37950901
[TBL] [Abstract][Full Text] [Related]
22. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev NS; Ainsworth G; Brown S; Pickering L; Waddell T; Fife K; Griffiths R; Sharma A; Katona E; Howard H; Velikova G; Maraveyas A; Brown J; Pezaro C; Tuthill M; Boleti E; Bahl A; Szabados B; Banks RE; Brown J; Venugopal B; Patel P; Jain A; Symeonides SN; Nathan P; Collinson FJ; Powles T
J Clin Oncol; 2024 Jan; 42(3):312-323. PubMed ID: 37931206
[TBL] [Abstract][Full Text] [Related]
23. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
25. Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma.
Takagi T
Int J Urol; 2023 Sep; 30(9):705-713. PubMed ID: 36479730
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
[TBL] [Abstract][Full Text] [Related]
27. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.
Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Hansen AR; Graham J; Soulières D; Reaume MN; Lalani AA; Castonguay V; Bjarnason GA; Patenaude F; Breau RH; Pouliot F; Kapoor A; Wood LA
Clin Genitourin Cancer; 2022 Jun; 20(3):210-218. PubMed ID: 35115252
[TBL] [Abstract][Full Text] [Related]
28. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Ficial M; Jegede OA; Sant'Angelo M; Hou Y; Flaifel A; Pignon JC; Braun DA; Wind-Rotolo M; Sticco-Ivins MA; Catalano PJ; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Wu CJ; Atkins MB; McDermott DF; Shukla SA; Choueiri TK; Signoretti S
Clin Cancer Res; 2021 Mar; 27(5):1371-1380. PubMed ID: 33219016
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
[TBL] [Abstract][Full Text] [Related]
30. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
32. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
34. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
35. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Khushalani NI; Diab A; Ascierto PA; Larkin J; Sandhu S; Sznol M; Koon HB; Jarkowski A; Zhou M; Statkevich P; Geese WJ; Long GV
Future Oncol; 2020 Oct; 16(28):2165-2175. PubMed ID: 32723187
[TBL] [Abstract][Full Text] [Related]
36. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
37. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
[TBL] [Abstract][Full Text] [Related]
38. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
39. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
[TBL] [Abstract][Full Text] [Related]
40. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
Verhaart SL; Abu-Ghanem Y; Mulder SF; Oosting S; Van Der Veldt A; Osanto S; Aarts MJB; Houtsma D; Peters FPJ; Groenewegen G; Van Herpen CML; Pronk LM; Tascilar M; Hamberg P; Los M; Vreugdenhil G; Polee M; Ten Tije AJ; Haanen JBAG; Bex A; van den Eertwegh AJ
Clin Genitourin Cancer; 2021 Jun; 19(3):274.e1-274.e16. PubMed ID: 33317946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
